Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. endocrinology
Show results for
Products
Services

Companies

News
Articles
Books

Refine by
Date

  • Older

Endocrinology Articles & Analysis

22 news found

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

“Apart from diabetes and hypertension management, there are currently very limited treatment options to slow kidney disease progression in people with chronic kidney disease and type 1 diabetes,” said Janet McGill, Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University, and Co-chair of the study’s Executive ...

ByBayer AG


Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline

Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline

His background spans a number of therapeutic categories including psychiatry, infectious disease, endocrinology, oncology and allergy. As co-founder and chief development officer of Park Therapeutics, Dr. ...

ByTris Pharma, Inc.


Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

(NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). ...

ByLumos Pharma


Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 ...

ByDiamyd Medical AB


Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study

("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of the StemSpine® ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

Preliminary (5 months) data on safety and endogenous insulin production have been published in the scientific journal Frontiers in Endocrinology. Updated 12-month results presented today at EASD The updated results provide additional support for a positive immunological and metabolic response in LADA patients with HLA DR3-DQ2. ...

ByDiamyd Medical AB


Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Carl Malchoff, Professor Emeritus, Medicine/Endocrinology, Founder of the Endocrine Neoplasia Program at UConn Health, and a co-author of the manuscript, “The addition of pairwise microRNA expression profiling represents a clinically important development in precision molecular diagnosis of indeterminate thyroid nodules. ...

ByInterpace Biosciences


Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Carl Malchoff, Professor Emeritus, Medicine/Endocrinology, Founder of the Endocrine Neoplasia Program at UConn Health, and a co-author of the manuscript, “The addition of pairwise microRNA expression profiling represents a clinically important development in precision molecular diagnosis of indeterminate thyroid nodules. ...

ByInterpace Biosciences


Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with ...

ByDiamyd Medical AB


Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients

Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients

The results of the research study have received academic recognition, are currently in pre-print for several journals and were presented as part of the European Congress of Endocrinology,. The project findings will serve as a valuable tool for patient advocacy groups and respective stakeholders in drawing the government's attention to the needs of Type 1 Diabetes patients in ...

ByLongenesis


Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams with New Appointments

Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams with New Appointments

Michael Crutchlow joins Kallyope after 15 years at Merck, where he most recently served as Executive Director, Late-Stage Clinical Research – Diabetes, Endocrinology and Metabolism following positions in clinical pharmacology, experimental therapeutics and early clinical biologics development. ...

ByKallyope Inc.


Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

“I look forward evaluating the use of LUM-201 for patients with NAFLD," said Laura Dichtel, MD, Assistant Professor, Harvard Medical School, Department of Endocrinology, Neuroendocrine Unit. "Prior studies have demonstrated growth hormone’s potential to treat NAFLD, given the hormone’s lipolytic actions in addition to its role as an anti-inflammatory cytokine. ...

ByLumos Pharma


AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

He serves as a reviewer for many journals including Diabetes, Pediatric Diabetes, and the Journal of Clinical Endocrinology and Metabolism. “My laboratory is very excited to collaborate with Dr. ...

ByAVM Biotechnology


Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes

“In this publication, we are beginning to get a picture of the long-term safety, tolerability, and metabolic benefits from the Revita procedure in patients who are poorly controlled on oral antidiabetic agents,” said David Hopkins, FRCP, Director of the Diabetes Endocrinology and Obesity Institute and Network, King’s Health Partners, London. ...

ByFractyl Health


Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

If ongoing studies are successful, it represents a potentially exciting treatment option to help achieve glycemic control in patients for whom the alternative would otherwise be insulin intensification,” said Vivian Fonseca, M.D., Chief of Endocrinology, Professor of Medicine and Pharmacology and Assistant Dean for Clinical Research at Tulane University. ...

ByFractyl Health


ILEX Medical to Invest 10 million NIS ($3.2 million)

ILEX Medical to Invest 10 million NIS ($3.2 million)

Today’s news is the latest in a series of milestones achieved during 2021, including a meeting with the FDA (INTERACT) earlier this month regarding IsletRx, receipt of a patent for the IsletRx technology from Japan, and the publishing of a scientific paper detailing the IsletRx program in the prestigious Frontiers in Endocrinology peer reviewed scientific journal. "We are ...

ByKadimastem Ltd.


Agplus Appoints New Chief Scientific Officer

Agplus Appoints New Chief Scientific Officer

This was quickly followed by a move to Endocrinology for 9 years as a senior research officer where numerous immunoassays were developed to determine the physiological functions of a number of hormones and neurotransmitters. ...

ByAgPlus Diagnostics Ltd


Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study

Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study

Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). ...

ByTissue Genesis


AOBiome Therapeutics Announces the Expansion of its Board of Directors

AOBiome Therapeutics Announces the Expansion of its Board of Directors

He is qualified as a professor of medicine at Heidelberg University, Germany, and he teaches internal medicine and endocrinology at the university. Anna Lisa Jenkins, MBBS, FCRP Dr. Jenkins, MBBS, FRCP is currently the Chief Executive Officer of PlaqueTec. ...

ByAOBiome Therapeutic, LLC


Could Hormone-Related Cancers Start Before Birth?

Thomas Zoeller, an expert in developmental endocrinology and endocrine-disruptors, and D. Joseph Jerry, an expert on the intersection of hormones and genetics, both at UMass Amherst. ...

ByNational Institute of Environmental Health Sciences (NIEHS)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT